biostudies-literatureUnknown29(9)Boisteau E<h4>Introduction</h4>Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy.<h4>Patients and methods</h4>We focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated.<h4>Results</h4>Poor independent prognostic factors were primary tumor in place, age <65 years and the presence of livThe oncologiste1149-e1158https://www.ebi.ac.uk/biostudies/studies/S-EPMC11379635biostudies-literatureClinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.PMC11379635Bourgeois VBoulatBernard PBouche OTaieb JDesgrippes RBaba-Hamed NLecaille CRemy SGranger VPlastaras LPigui ABaconnier MBelletierBouhier-Leporrier KWalter TCattan SFollana PCavaglione GRinaldi YVilling ALHollebecque APetorin CDevaure IHebbar MAndrau PFarneti DThomas Marques LBonnet IWilliet NLledo GLe Malicot KBreysacher GLocher CDesauwDesrame JDuluc MLagasse JPBaize NDupont Gossart ACCeban TSverdlin REvesque LPRODIGE 35 Investigator/CollaboratorsBoisteau ECorbinais SHocine FDucreux MLecomte TVimal-Baguet AGigout JSimon MAparicio TFerte CBoige VTopolski AAudemar FLombard-Bohas CMary FDahan LSefrioui DArsenii NGuilngar ANorguet EMoullet IDeplanque GLe Roy FBignon ALJouve JLMeunier JLepage CFrancois ERomano OCharlois TSeitz JFEzenfis JPezet DCumin ICornila CMichel PEscande AMolin YBarriere NGuillet MSibertin-Blanc CRebischung CFoll LTurpin AMalka DDupont Kazma LDuchmann JCArtru PLegoux JLCoufon CBedenne LBurtin PZaanan ADurand AStaudacher LTalarmin MPracht MBerdah SLievre ABachet JBLe Sourd SfalseClinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.<h4>Introduction</h4>Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy.<h4>Patients and methods</h4>We focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated.<h4>Results</h4>Poor independent prognostic factors were primary tumor in place, age <65 years and the presence of liv2024-01-01T00:00:00Z2024 Sep2026-07-15T05:35:22.189Z2025-04-05T13:58:07.146ZS-EPMC113796353923532610.1093/oncolo/oyae079